PAT for the Future of Oligonucleotide Manufacturing - METTLER TOLEDO
On Demand Webinar

PAT for the Future of Oligonucleotide Manufacturing

On Demand Webinar

In-situ FTIR as a Process Transform Synthesizer at Avecia

PAT For the Future of Oligonucleotide Manufacturing
PAT For the Future of Oligonucleotide Manufacturing

Avecia has played an integral role in advancing the oligonucleotide therapeutic market over the past 20 years. Avecia's experience in oligonucleotide development and manufacturing has produced over 1000 successful tract oligonucleotide sequences. Avecia's mission is to innovate and build value as customers' needs progress through drug development into commercialization. There are many process and chemistry challenges for oligonucleotide manufacturing which result in low purities, yields and throughputs as well as high costs and waste of raw materials (amidites and solvents). In 2017, Avecia started the Technology Innovation & Improvement Management (TIIM) group focused to address these manufacturing challenges.

The presentation provides insights from the TIIM’s initiatives on the fundamental changes that Avecia is proposing and planning to implement to address these manufacturing challenges. TIIM at Avecia is currently building newer, efficient, continuous manufacturing process that are intended to reach higher purities, yields and throughputs while reducing COGS. Emerging platforms are built on new synthesizer and alternative purification technologies with full automation. PAT as an enabling technology for the future of oligo manufacturing is discussed.

Join the hundreds of researchers who already viewed the presentation. 

Dr. Karsten Keller – Nitto Denko Avecia
28 Minutes
English

This page is not optimized for your web browser. Consider using a different browser or upgrade your browser to the latest version to ensure the best experience.